Study | Country Study period |
Population source | Exposure definition | Non-exposure definition | Sample size | Rmk |
---|---|---|---|---|---|---|
Ahlqvist (Population-Based), 2024 |
Sweden 1995 - 2019 |
All singleton liveborn children in Sweden from July 1, 1995, to December 31, 2019, with a linkable personal identifier. | Children exposed to acetaminophen (ATC: N02BE) during pregnancy (ever-use). |
unexposed (general population or NOS)
Children not exposed to acetaminophen (ATC: N02BE) during pregnancy. |
185909 / 2294888 | |
Ahlqvist (Sibling), 2024 |
Sweden 1995 - 2019 |
All singleton liveborn children in Sweden from July 1, 1995, to December 31, 2019, with a linkable personal identifier. | Sibling cohort: Offspring of pregnant individuals who had discordant acetaminophen (ATC: N02BE) use across pregnancies, and with use of acetaminophen during pregnancies. |
sibling
Sibling cohort: Offspring of pregnant individuals who had discordant acetaminophen (ATC: N02BE) use across pregnancies, and no use of acetaminophen during pregnancies. |
-9 / -9 | Results of the Sibling cohort reported here. Number of offsprings in each group of exposure not provided. |
Alemany_DNBC, 2021 |
Denmark 1996 - 2002 |
Pregnant women enrolled through their general practitioners during early gestation (weeks 6 to 12). | Mothers that used acetaminophen during pregnancy at any dose and at any time up during pregnancy. |
unexposed (general population or NOS)
Mothers that did not use acetaminophen during pregnancy. |
34584 / 26846 | For ADHD and ASDdiag: Overlapping: original data published by Liew 2014; Inoue 2021 ans Liew 2016b=> not reported here; but ASDrisk outcome reported here because not provided in other studies. |
Bertoldi_Pelotas, 2020 |
Brazil Jan - Dec 2015 |
Pregnant women recruited during antenatal care (73.8%) (before 16 weeks) or for those not already enrolled: women who gave birth in any of the 5 maternity hospitals of the city of Pelotas from 1 January to 31 December 2015. | Any use of acetaminophen in 1st, 2nd, and/or 3rd trim rimester of pregnancy. |
unexposed (general population or NOS)
No use of acetaminophen in 1st, 2nd, and/or 3rd trim rimester of pregnancy. |
2470 / 1348 | Bêtas are reported. OR were calculated based on mean, sd and n. Women recruited prenatally (before 16 weeks of gestation) and perinatal (hours after delivery). => 73.8% of the mothers enrolled prenatally. => Considered as prospective cohort. |
Inoue, 2021 |
Denmark 1996 - 2002 |
Live-born children whose mothers answered the study enrollment form and the 3 subsequent telephone interviews after to be enrolled in the cohort at their first general-practitioner antenatal visit (during weeks 6–12). | Children of mothers that reported use of acetaminophen at least once during pregnancy. |
unexposed (general population or NOS)
Children of mothers that did not report use of acetaminophen during pregnancy. |
21670 / 19264 | Overlapping: for ADHD risk => use of the same dataset and same tool (SDQ) than data in Alemany 2024 (younger children) => use of Inoue 2021. Use of parents-reported outcome adjusted for parents’ behavioral problems in childhood. |
Liew, 2014 |
Denmark 1996 - 2002 |
Singleton live born children whose mothers participated in all three telephone interviews after being recruited through their general practitioners (about 50% of all general practitioners in Denmark participated in the study) during early gestation (weeks 6–12). | Children born to mothers who reported use of acetaminophen during the entire pregnancy or during the first (1-12 weeks), second (13-24 weeks), or third (25th-delivery) trimester. |
unexposed (general population or NOS)
Children born to mothers who never used acetaminophen during pregnancy or the reported period of exposure. |
36187 / 28135 | Methods completed with Liew 2016. Overlapping: For ADHD: Liew 2016a studied Attention and Liew 2014 studies ADHD medication or hyperkinetic disorder (with same dataset) => only 1 result reported: the most global and robust: i.e Liew 2014 (ICD-10). |
Liew a, 2016 |
Denmark 1996 - 2002 |
Singleton live-born of pregnancies enrolled at the first general practitioner antenatal visit (during weeks 6 to 12). The LDPS sampling was based on maternal alcohol and binge drinking reported during pregnancy (by timing and amount of consumptions) with an oversampling strategy to select the high-alcohol-exposed subgroup. | Children born to mothers who used acetaminophen during pregnancy (ever use, trimester of use, and total weeks of use). |
unexposed (general population or NOS)
Children born to mothers who never used acetaminophen during pregnancy. |
881 / 610 | Authors provided: Mean Difference (95% CI). OR based on R package 'compute.es'. Methods completed with Liew 2016a, b and c. |
Liew b, 2016 |
Denmark 1996 - 2002 |
Singleton live born children whose mothers participated in all three telephone interviews after being recruited through their general practitioners (about 50% of all general practitioners in Denmark participated in the study) during early gestation (weeks 6–12). | Children of women with maternal acetaminophen use during pregnancy. |
unexposed (general population or NOS)
Children of women who did not use acetaminophen while pregnant. |
36187 / 28135 | Methods completed with Liew 2016a, b and c. Data on Asperger syndrome (F84.5), and Pervasive Developmental Disorder not otherwise specified (PDD-NOS) not reported here because only provided by subgroup (with or without hyperkinetic disorder). |
Sznajder, 2022 |
USA 2009 - 2011 |
Pregnant women (first pregnancy > 20 GW) age 18 to 35 at the time of recruitment, English or Spanish speaking, and planning to deliver at one of the 78 hospitals in Pennsylvania. | Pregnant women who reported using acetaminophen during pregnancy. |
unexposed (general population or NOS)
Pregnant women who did not report using acetaminophen during pregnancy. |
1011 / 1411 | |
Tovo-Rodrigues, 2018 |
Brazil Jan - Dec 2004 |
Mothers who living in the urban area of Pelotas or in Jardim América, southern Brazil. | Mothers that was used medication composed of acetaminophen at least once during pregnancy. |
unexposed (general population or NOS)
Mothers that did not use medication composed of acetaminophen during pregnancy. |
965 / 2505 | N1/N0 at 6 years. For Emotional, behavioral and ADHD: Overlapping between Tovo-Rodriguez 2018 and 2020 (same population, same outcomes, 2 different tools and different ages), use of Tovo-Rodriguez 2018 because older children (6-11 years versus 48 months). |
Tovo-Rodrigues, 2020 |
Brazil Jan - Dec 2004 |
Mothers who living in the urban area of Pelotas or in Jardim América, interviewed within 24 hours after delivery. | Mothers that use acetaminophen at least once during pregnancy, regardless of the dose used. |
unexposed (general population or NOS)
Mothers that did not use acetaminophen during pregnancy. |
1060 / -9 | N0 ?. For Emotional, behavioral and ADHD: Overlapping between Tovo-Rodriguez 2018 and 2020 (same population, same outcomes, 2 different tools and different ages), use of Tovo-Rodriguez 2018 because older children (6-11 years compared with 48 months). |
Tronnes, 2020 |
Norway 1999 - 2008 |
Pregnant women recruited in Norway between 1999 and 2008 at their routine ultrasound examination at gestational week 17‐18. | Mothers who had used paracetamol at least once during the pregnancy (in one trimester, in two trimesters or in three trimesters). |
unexposed (general population or NOS)
Mothers who did not use paracetamol during pregnancy (mutually exclusive groups). |
15126 / 17808 | Authors provided 3 durations of use: in 1 trimester; in 2 trimesters; in 3 trimesters (without global analysis of whole exposure) => use of the duration more comparable with other studies and more pregnancies (i.e in 1 trimester). |
Vlenterie, 2016 |
Norway 1999 - 2008 |
All live-born singletons of the mothers including in the MoBa cohort, giving birth before 2009 except for infants born with major congenital malformations and infants with missing questionnaire information. | Infants with in utero paracetamol exposure: short-term exposure (1–27 days) or long-term exposure (28 days or more). |
unexposed (general population or NOS)
Infants without in utero paracetamol exposure. |
20749 / 30451 | Non motor outcomes: Overlapping: same dataset, outcomes and tools than in Tronnes 2020 (older children) => use of Tronnes. 2 durations of use provided: use of the duration more comparable with other studies (i.e < 28 days). Use of motor milestone outcome. |
Woodbury a, 2024 |
USA 2013 - 2020 |
Pregnant participants, <15 weeks of gestation recruited at two local obstetric clinics and gave birth at two local hospitals, at their first prenatal visit. | Participants that took acetaminophen during pregnancy. |
unexposed (general population or NOS)
Participants that did not take acetaminophen during pregnancy. |
377 / 155 | Results of the Speech and Language Assessment Scale at 3 years not reported here because provided as continuous values. Use of Expressive vocabulary, because: use in the short version of the MBCDI and other scales mostly measure expressive vocabulary. |
Ystrom or Gustavson (Gustavson 2021 - Sibling), 2017 |
Norway 1999 - 2008 |
Pregnant women from all over Norway recruited between 1999 and 2008 when they were invited to their routine ultrasound examination in gestational week 17. | Sibling children exposed to Acetaminophen (ATC code N02BE01) during pregnancy. |
sibling
Sibling children not exposed to Acetaminophen (ATC code N02BE01) during pregnancy. |
7988 / 15165 | Authors provided 3 durations of use: 1-7 days; 8-28 days; >= 29 days (without global analysis of whole exposure) => use of the duration more comparable with other studies and more pregnancies (i.e 1-7 days). |
Ystrom or Gustavson (Ystrom - Population-Based), 2017 |
Norway 1999 - 2009 |
Pregnant women in Norway who consented to participate after being invited by mail in connection with the routine ultrasound examination offered at the local hospitals around pregnancy week 18. | Pregnant women that reported use of acetaminophen during pregnancy. |
unexposed (general population or NOS)
Pregnant women that reported never use of acetaminophen during pregnancy. |
52707 / 60266 | Overlapping: Gustavson 2019 and Stoltenberg 2020 => 2 ad hoc studies (dedicated to fever indication and methodological one, respectively) essentially based on the same dataset than Ystrom 2017 (prenatal acetaminophen and ADHD) => use of Ystrom 2017. |
Study | Country Study period |
Case | Control | Sample size | Rmk |
---|---|---|---|---|---|
Chen, 2019 |
Taiwan 1998 - 2008 |
Children who received diagnoses of Attention-Deficit/Hyperactivity Disorder (ICD-9-CM code: 314) by board-certified psychiatrists on the basis of diagnostic interviews and clinical judgement. | Children who did not receive diagnosis of Attention-Deficit/Hyperactivity Disorder randomly (1:4) identified on the basis of the mothers’ ages, children’s sex and ages, mothers’ age during pregnancy, income, and urbanization level. | 950 / 3800 |